ALDH18A1

Across TCGA pan-cancer cohorts, ALDH18A1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ALDH18A1 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher ALDH18A1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ALDH18A1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, GBM, and ACC are the cancer types where ALDH18A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.022	0.701	<.001	12	view →
GBM	OS	Median	All	0.005	0.416	<.001	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
COAD	DFS	Median	II,III,IV	0.200	0.648	.019	3	view →
UCEC	DFS	Median	All	0.967	0.830	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ALDH18A1–ESCA (OS)

Open the ESCA breakdown →